Request Demo

Last update 08 Oct 2025

Ipilimumab

Last update 08 Oct 2025

Overview

R&D Status

Clinical Result

Translational Medicine

Overview

Basic Info

Drug Type

Monoclonal antibody

Synonyms

Anti CTLA-4 monoclonal antibody, Anti-CTLA-4 Mab, Ipilimumab (Genetical Recombination)

+ [17]

Target

CTLA4

Action

inhibitors

Mechanism

CTLA4 inhibitors(Cytotoxic T-Lymphocyte-Associated Antigen 4 inhibitors)

Therapeutic Areas

NeoplasmsDigestive System DisordersRespiratory Diseases+ [12]

Active Indication

Microsatellite instability-high Rectal CancerPD-L1 positive Non-Small Cell Lung CancerMetastatic hepatocellular carcinoma+ [304]

Inactive Indication

Acute lymphoblastic leukemia recurrentAcute Promyelocytic LeukemiaAdenocarcinoma, metastatic+ [121]

Originator Organization

Bristol Myers Squibb Co.

Active Organization

National Cancer Institute

Bristol Myers Squibb Co.

The University of Texas MD Anderson Cancer Center

+ [16]

Inactive Organization

National Institutes of Health Clinical CenterJonsson Comprehensive Cancer Center

Checkmate Pharmaceuticals, Inc.

+ [11]

License Organization

Nektar Therapeutics

Inspirna, Inc.

Gritstone bio, Inc.

+ [8]

Drug Highest PhaseApproved

First Approval Date

United States (25 Mar 2011),

Melanoma

RegulationPriority Review (United States), Breakthrough Therapy (United States), Fast Track (United States), Accelerated Approval (United States), Orphan Drug (United States), Priority Review (China), Breakthrough Therapy (China), Orphan Drug (South Korea), Priority Review (Australia), Conditional marketing approval (China), Orphan Drug (Japan)

Structure/Sequence

Sequence Code 143797L

Source: *****

Sequence Code 9060585H

Source: *****

870

Clinical Trials associated with Ipilimumab

NCT07128680

/ Not yet recruitingPhase 1IIT

A Randomized Study of Nivolumab and Ipilimumab With and Without EXL01 in First-Line Treatment of Metastatic Renal Cell Carcinoma (mRCC)

This phase I trial tests the safety and effectiveness of nivolumab and ipilimumab with and without EXL01 for the treatment of renal cell cancer that has spread from where it first started (primary site) to other places in the body (metastatic). Immunotherapy with monoclonal antibodies, such as nivolumab and ipilimumab, may help the body's immune system attack the tumor, and may interfere with the ability of tumor cells to grow and spread. EXL01 is a live biotherapeutic product containing a strain of bacteria called Faecalibacterium prausnitzii. It may enhance a patient's response to treatment with immune checkpoint inhibitors like nivolumab and ipilimumab by altering the composition of the bacteria in the gut. Adding EXL01 to treatment with nivolumab and ipilimumab may be safe and more effective than giving nivolumab and ipilimumab alone.

Start Date05 Dec 2025

Sponsor / Collaborator

City of Hope National Medical Center

[+1]

NCT07188896

/ Not yet recruitingPhase 2IIT

A Randomized Phase 2 Trial of Fianlimab and Cemiplimab +/- Ipilimumab or Ipilimumab Plus Nivolumab in First-line Advanced Renal Cell Carcinoma (RCC)

This three-arm randomized phase 2 trial will enroll advanced clear cell RCC patients (all IMDC risk groups). Patients will be randomized 2:2:1 to either Arm A (fianlimab/ cemiplimab/ ipilimumab), Arm B (fianlimab/ cemiplimab), or Arm C (standard ipilimumab/ nivolumab), respectively.

Start Date01 Nov 2025

Sponsor / Collaborator

Hoosier Cancer Research Network

[+2]

NCT07155317

/ Not yet recruitingPhase 2IIT

The TIME Trial - Phase II Randomized Controlled Trial of Time-of-Day Specified Immunotherapy for Advanced Melanoma

This phase II trial tests the safety and effectiveness of giving ipilimumab and nivolumab in the morning compared to other times of day in treating patients with melanoma that is stage IV or that cannot be removed by surgery (unresectable). Immunotherapy with monoclonal antibodies, such as ipilimumab and nivolumab, may help the body's immune system attack the tumor and may interfere with the ability of tumor cells to grow and spread. While some patients have impressive outcomes with both of these drugs, over 40% of patients do not experience any clinical benefit. Studies have shown that the time of day that vaccines and other therapies are given have had an impact on response and survival. It is not known, however, whether time of day has an impact on response to immune checkpoint inhibitors, such as ipilimumab and nivolumab. Giving ipilimumab and nivolumab earlier in the day compared to later in the day may improve response to treatment and survival in patients with stage IV or unresectable melanoma.

Start Date29 Oct 2025

Sponsor / Collaborator

Emory University

[+1]

100 Clinical Results associated with Ipilimumab

100 Translational Medicine associated with Ipilimumab

100 Patents (Medical) associated with Ipilimumab

5,654

Literatures (Medical) associated with Ipilimumab

31 Dec 2025·OncoImmunology

Immune-related hepatitis and hypophysitis are associated with superior survival in melanoma patients treated with combined ipilimumab and nivolumab

Article

Author: Bjursten, Sara ; Ny, Lars ; Lindén, Maria ; Levin, Max ; Zhao, Zhiyuan ; Pandita, Ankur ; Al Remawi, Hifaa ; Rudin, Anna

Combination CTLA-4 (ipilimumab) and PD-1 (nivolumab) checkpoint inhibition (dual-ICI) improves survival in patients with advanced melanoma. However, many patients also experience immune-related adverse events (irAE) that require systemic treatment with corticosteroids. Corticosteroids dampen the anti-tumoral response and may impair survival. Here, we investigated the association between irAE and overall survival as well as exposure to corticosteroids and second line immunosuppressants in dual ICI-treated patients with advanced melanoma (n = 205). Patients with irAE (n = 113) had superior OS compared to patients with no irAE (n = 92). The survival benefit persisted after adjusting for immortal time bias. Regarding specific irAE, patients with colitis, hepatitis, rheumatic irAE, hypophysitis, and skin-related irAE had improved OS after adjusting for negative baseline factors. A survival benefit persisted for hypophysitis (p = 0.03) and hepatitis (p = 0.04) after adjusting for immortal time bias, whereas rheumatic (p = 0.05) and skin-related irAE (p = 0.06) where borderline significant. Hepatitis and colitis required higher doses of corticosteroids for longer times and more often second-line immunosuppression compared to other irAE. In conclusion, irAE are associated with superior OS in patients with advanced melanoma treated with dual ICI. Hepatitis and hypophysitis were most strongly associated with better survival outcomes. Studies investigating the mechanisms underlying hepatitis and hypophysitis may identify important response mechanisms.

31 Dec 2025·OncoImmunology

Circulating cytokine associations with clinical outcomes in melanoma patients treated with combination nivolumab plus ipilimumab

Article

Author: Baginska, Joanna ; Rodig, Scott J. ; Hodi, F. Stephen ; Severgnini, Mariano ; Manuszak, Claire ; Brennick, Ryan ; Chen, Jiajia ; Weirather, Jason L. ; Manos, Michael ; Ranasinghe, Srinika ; Liu, David ; Huang, Amy Y. ; Holovatska, Marta ; Hathaway, Emma ; Nazzaro, Matthew ; Giobbie-Hurder, Anita ; Tarantino, Giuseppe ; Russell, Janice D. ; Pfaff, Kathleen L.

Nivolumab plus ipilimumab (aCTLA-4/aPD-1) combination therapy has significantly improved clinical outcomes in patients with metastatic melanoma, with 50%-60% of patients responding to treatment, but predictors of response are poorly characterized. We hypothesized that circulating cytokines and peripheral white blood cells may predict response to therapy and evaluated 15 cytokines and complete blood counts (CBC with differentials) from 89 patients with advanced melanoma treated with combination therapy from three points in time: pre-treatment, one month and approximately three months after starting therapy. Clinical endpoints evaluated included durable clinical benefit (DCB), progression-free survival (PFS), and overall survival (OS). A parsimonious predictive model was developed to identify cytokines predictors of response to combination therapy. In this study, we found that pre-treatment, patients with DCB had higher IL-23, lower CXCL6, and lower IL-10 levels. Lower NLR one month after starting therapy predicted better PFS and OS, primarily driven by an increase in absolute lymphocytes. A multivariate model demonstrated that baseline CXCL6, IL-10, IL-23 were independent predictors of therapy response, and the combined model has reached an area under the curve (AUC) of 0.79 in prediction of response to combination therapy. Our study identified baseline CXCL6, IL-23, and IL-10 as predictors of response to aCTLA4/aPD1 combination therapy among patients with metastatic melanoma. This study also provides a framework for identifying patients who are likely to respond to combination ICB, as well as a subset of patients with high risk of developing resistance and are thus in need of alternative therapeutic options, such as clinical trials.

31 Dec 2025·mAbs

Engineered ipilimumab variants that bind human and mouse CTLA-4

Article

Author: Barman, Ishita ; Lee, Peter S. ; Diong, SJ ; Bee, Christine ; Rajpal, Arvind ; Kumar, Anusha ; West, Sean M. ; Strop, Pavel ; Robison, Brett ; Chau, Bryant ; Chang, Olin ; Korman, Alan J. ; Moon, Thomas M.

Testing of candidate monoclonal antibody therapeutics in preclinical models is an essential step in drug development. Identification of antibody therapeutic candidates that bind their human targets and cross-react to mouse orthologs is often challenging, especially for targets with low sequence homology. In such cases, surrogate antibodies that bind mouse orthologs must be used. The antibody 9D9, which binds mouse CTLA-4, is a commonly used surrogate for CTLA-4 checkpoint blockade studies in mouse cancer models. In this work, we reveal that 9D9 has significant biophysical dissimilarities to therapeutic CTLA-4 antibodies. The 9D9-mCTLA4 complex crystal structure was determined and shows that the surrogate antibody binds an epitope distinct from ipilimumab and tremelimumab. In addition, while ipilimumab has pH-independent binding to hCTLA-4, 9D9 loses binding to mCTLA-4 at physiologically relevant acidic pH ranges. We used phage and yeast display to engineer ipilimumab to bind mouse CTLA-4 with single-digit nM affinity from an initial state with no apparent binding. The engineered variants showed pH-independent and cross-reactive binding to both mouse and human CTLA-4. Crystal structures of a variant in complex with both mouse and human CTLA-4 confirmed that it targets an equivalent epitope as ipilimumab. These cross-reactive ipilimumab variants may facilitate improved translatability and future mechanism-of-action studies for anti-CTLA-4 targeting in murine models.

890

News (Medical) associated with Ipilimumab

06 Oct 2025

·www.globenewswire.com

Exicure Highlights Recent Achievements and Near-term Strategic Priorities

Burixafor (GPC-100) Phase 2 Trial in Multiple Myeloma Nears Key Readout Preparing for Expansion into Sickle Cell Disease and Acute Myeloid Leukemia New Leadership Appointments Bring Deep Drug Development Expertise REDWOOD CITY, Calif., Oct. 06, 2025 (GLOBE NEWSWIRE) -- Exicure, Inc. (Nasdaq: XCUR), a clinical-stage biotechnology company developing therapeutics for hematologic diseases, today shared recent progress for its lead program, burixafor (GPC-100), outlined upcoming strategic priorities, and introduced new members of its leadership team who will help drive the company’s next phase of growth. “The progress we’ve achieved since integrating GPCR Therapeutics earlier this year reflects both the strength and potential of the burixafor program and the dedication of our team,” said Andy Yoo, Chief Executive Officer of Exicure. “As we look ahead to our upcoming Phase 2 data readout and plan for expansion into new indications, I am energized by the opportunity to advance a program that could transform treatment approaches across multiple diseases.” Burixafor Phase 2 Trial in Multiple Myeloma Nears Key Clinical Readout Exicure’s ongoing Phase 2 study (NCT05561751) is a randomized, open-label, multicenter trial evaluating burixafor, a small molecule CXCR4 antagonist, in autologous stem cell transplant (ASCT) for multiple myeloma. By blocking CXCR4, burixafor is designed to mobilize hematopoietic stem cells out of the bone marrow and into the bloodstream, where they can be collected for use in transplant procedures. Interim results to date have been highly encouraging, with 100% of patients (10/10) achieving the primary endpoint of successful CD34+ stem cell mobilization, including patients previously treated with daratumumab. Burixafor has a faster kinetics of mobilization with a well-tolerated safety profile, enabling same-day administration of the mobilizing agent and leukapheresis. This differentiates burixafor from FDA-approved agents such as plerixafor and motixafortide, which require overnight pre-treatment. In August, the company announced that the final patient had completed their last study visit. The clinical database has since been locked, and Exicure remains on track to report topline data in Q4 2025. Preparations are also underway for a potential Phase 3 trial. A full data publication from the ongoing Phase 2 trial (NCT05561751) is anticipated in 2026. In addition, a publication from a previous Phase 2 study (NCT02104427) evaluating burixafor in combination with G-CSF in patients with multiple myeloma, non-Hodgkin lymphoma, and Hodgkin disease, is currently under peer review. Expanding Development Opportunities Building on progress in multiple myeloma, Exicure is preparing to expand burixafor into additional indications: Sickle Cell Disease: Exicure is in discussions with key clinicians at leading institutions to initiate an investigator-sponsored trial evaluating burixafor for improving stem cell mobilization in patients undergoing gene editing and autologous transplant.Acute Myeloid Leukemia (AML): The company is also planning a Phase 1 chemosensitization study in AML. Preclinical data suggest that burixafor may mobilize tumor cells from protective bone marrow niches, potentially enhancing the efficacy of chemotherapy. New Leadership Strengthen Scientific and Clinical Capabilities Following its acquisition of GPCR Therapeutics USA earlier this year, Exicure has been advancing the Phase 2 trial with dedicated internal drug development experts. These scientific leaders bring broad experience spanning from basic research to regulatory approval and have decades of proven track records in developing innovative medicines. Josephine (Pina) Cardarelli, Ph.D. joined as President and Chief Scientific Officer. Dr. Cardarelli is a seasoned drug development executive whose career spans oncology, immunology, pharmacology, and translational medicine. She most recently served as Vice President of Cell Biology & Pharmacology at Bristol-Myers Squibb, where she played a key role in the approvals of Yervoy® and Opdivo® and Fucosyl GM-1 antibody program that is currently in Phase 3. Earlier in her career at Medarex, she advanced multiple programs into clinical development, including CXCR4 (Ulocuplumab), CXCL10, CD30, and CD19 antibodies and multiple ADCs. She also identified the lead antibody for the IFNα receptor program that ultimately became AstraZeneca’s FDA-approved Saphnelo™. With more than 100 global patents and over 50 peer-reviewed publications, Dr. Cardarelli brings extensive expertise in biologics, antibody-drug conjugates, IND strategy, and regulatory affairs. She received her Ph.D. in physiology from Albany Medical College. Niña Caculitan, Ph.D. has been appointed Head of Clinical, overseeing activities spanning manufacturing, regulatory affairs, clinical development, clinical operations and data analysis. She brings over 15 years of experience from both academia and industry, with a strong background in antibody and small molecule chemistry for therapeutics in oncology and immune-mediated disorders. Previously, she was a key contributor to understanding cellular mechanisms of antibody drug conjugate processing at Genentech. Dr. Caculitan earned her Ph.D. in chemistry from the University of California, Berkeley. Devki Sukhtankar, Ph.D. has joined as Head of Preclinical Research and Translational Medicine, guiding cross-functional translational research efforts with a focus on integrating clinical data and advancing the pipeline into new indications. She brings over 15 years of experience in oncology, neurology and inflammatory diseases, where she has led preclinical programs with a focus on pharmacology and contributed to 20 peer-reviewed publications. Dr. Sukhtankar earned her Ph.D. in cancer biology from the University of Arizona and has extensive experience collaborating with partner organizations to expand therapeutic opportunities. About Burixafor (GPC-100)Burixafor (GPC-100) is a highly selective small molecule antagonist of CXCR4, a chemokine receptor that plays a central role in retaining hematopoietic stem cells in the bone marrow niche. By blocking CXCR4, burixafor may enhance the mobilization of these cells into the peripheral blood for collection and use in autologous stem cell transplant (ASCT) procedures. Originally developed by GPCR Therapeutics, Inc., burixafor became part of Exicure’s pipeline following the company’s acquisition in January 2025. In addition to multiple myeloma, burixafor is also being considered in other diseases where improved stem cell mobilization could help enable more efficient and effective treatment approaches, such as sickle cell disease, rare diseases requiring autologous transplant, and cell and gene therapy settings. A chemosensitization trial in AML is also being planned, leveraging burixafor’s mechanism of mobilizing malignant cells from protective bone marrow niches into the peripheral blood, where they may be more effectively targeted by chemotherapy. About Exicure Exicure, Inc. (Nasdaq: XCUR) is a clinical-stage biotechnology company developing therapies to address key challenges in hematologic diseases. The company’s lead program, burixafor (GPC-100), is being evaluated for its ability to improve stem cell mobilization in multiple myeloma, sickle cell disease, and in support of cell and gene therapy. It is also being studied as a potential chemosensitizing agent in acute myeloid leukemia (AML). For more information, visit www.exicuretx.com. Contact:Exicure, Inc.847.673.1700 (Tel)847.556.6411 (Fax)

Phase 2Phase 1Phase 3AcquisitionImmunotherapy

22 Sep 2025

·www.businesswire.com

Delcath Systems Announces Investigator-Initiated CHOPIN Phase 2 Trial Presentation at ESMO 2025 Congress

QUEENSBURY, N.Y.--(BUSINESS WIRE)--Delcath Systems, Inc. (NASDAQ: DCTH), an interventional oncology company focused on the treatment of primary and metastatic liver cancers, today announced the acceptance of an oral presentation on results from the investigator-initiated CHOPIN randomized Phase 2 trial at the 2025 European Society for Medical Oncology (ESMO) Annual Congress. Principal Investigator Ellen Kapiteijn, MD, from Leiden University Medical Center’s Department of Medical Oncology, will present data evaluating the safety, tolerability, and efficacy of sequencing systemic ipilimumab and nivolumab with Delcath’s CHEMOSAT® Hepatic Delivery System for percutaneous hepatic perfusion with melphalan in patients with metastatic uveal melanoma. Title: Combined Percutaneous Hepatic Perfusion with Ipilimumab plus Nivolumab in Metastatic Uveal Melanoma: a single center, open-label, randomized, phase 2 study (CHOPIN) Session Title: Melanoma and other skin tumours Session Date and Time: Saturday, October 18, 2025 3:20 p.m. CET / 9:20 a.m. EST Abstract Number: LBA59 Presenter: Ellen Kapiteijn, MD The poster will be available at https://delcath.com/investors/events-presentations/ when the ESMO embargo is released on October 18, 2025. About Delcath Systems, Inc., HEPZATO KIT, and CHEMOSAT Delcath Systems, Inc. is an interventional oncology company focused on the treatment of primary and metastatic liver cancers. The company’s proprietary products, HEPZATO KITTM (HEPZATO (melphalan) for Injection/Hepatic Delivery System) and CHEMOSAT® Hepatic Delivery System (HDS) for Melphalan percutaneous hepatic perfusion (PHP), are designed to administer high-dose chemotherapy to the liver while controlling systemic exposure and associated side effects during a PHP procedure. In the United States, HEPZATO KIT is considered a combination drug and device product and is regulated and approved for sale as a drug by the FDA. HEPZATO KIT is comprised of the chemotherapeutic drug melphalan and Delcath’s proprietary HDS. The HDS is used to isolate the hepatic venous blood from the systemic circulation while simultaneously filtrating hepatic venous blood during melphalan infusion and washout. The use of the HDS results in loco-regional delivery of a relatively high melphalan dose, which can potentially induce a clinically meaningful tumor response with minimal hepatotoxicity and reduce systemic exposure. HEPZATO KIT is approved in the United States as a liver-directed treatment for adult patients with metastatic uveal melanoma (mUM) with unresectable hepatic metastases affecting less than 50% of the liver and no extrahepatic disease, or extrahepatic disease limited to the bone, lymph nodes, subcutaneous tissues, or lung that is amenable to resection or radiation. Please see the full Prescribing Information, including BOXED WARNING for the HEPZATO KIT. In Europe, the device-only configuration of the HDS is regulated as a Class III medical device and is approved for sale under the trade name CHEMOSAT Hepatic Delivery System for Melphalan, or CHEMOSAT, where it has been used in the conduct of percutaneous hepatic perfusion procedures at major medical centers to treat a wide range of cancers of the liver. Forward-Looking Statements This release contains forward-looking statements, including statements regarding the expected release of clinical trial results, which are subject to risks and uncertainties. Factors that could affect these forward-looking statements include, but are not limited to, delays in the presentation of the data, or other unforeseen issues relating to the release of the clinical trial results. For a detailed discussion of these and other risks, please refer to Delcath’s filings with the SEC.

Phase 2Drug ApprovalClinical Result

19 Sep 2025

·www.prnewswire.com

Liver Cancer Therapeutics Market Size Surpasses USD 13.16 Billion by 2032, Increasing at a CAGR of 16.5% from 2025 to 2033

AUSTIN, Texas and TOKYO, Sept. 19, 2025 /PRNewswire/ -- According to DataM Intelligence, the global liver cancer therapeutics market size was valued at US$3.36 billion in 2024 and is expected to reach US$13.16 billion by 2033, growing at a CAGR of 16.5% during the forecast period 2025-2033. The liver cancer therapeutics market is entering a transformative phase, driven by the shift from traditional systemic therapies to innovative immunotherapies and targeted agents that offer improved survival outcomes. The growing adoption of combination regimens, particularly checkpoint inhibitors paired with VEGF or TKI therapies, is expected to redefine the treatment landscape and expand the eligible patient pool. At the same time, the rising prevalence of hepatocellular carcinoma worldwide, coupled with strong R&D pipelines and increasing regulatory approvals, positions this market for sustained growth. A significant advancement in liver cancer therapeutics is the approval of combination immunotherapy regimens. Notably, AstraZeneca's Imfinzi (durvalumab) plus Imjudo (tremelimumab) gained global recognition after the HIMALAYA trial demonstrated a meaningful overall survival benefit in patients with unresectable hepatocellular carcinoma. This approval provided a new first-line treatment option beyond tyrosine kinase inhibitors and VEGF-targeted therapies, offering durable survival outcomes for a subset of patients and reshaping the standard of care in advanced HCC. Another key advancement is the expansion of targeted oral therapies, which have improved safety and efficacy profiles. Drugs such as lenvatinib and cabozantinib have demonstrated substantial clinical activity as first- or second-line options, while ongoing research is investigating their use in combination with checkpoint inhibitors. The growing pipeline of next-generation TKIs and precision therapies, tailored to genetic and molecular profiles, is driving innovation, improving patient survival, and reinforcing the importance of oral targeted agents in the long-term management of HCC. Get a Sample PDF Brochure of the Report (Use Corporate Email ID for a Quick Response): The chemotherapy segment, based on therapy type, is expected to account for 39.1% of the liver cancer therapeutics market share. Chemotherapy remains a vital part of the liver cancer therapeutics market, especially for patients with intermediate-stage hepatocellular carcinoma (HCC) or those ineligible for surgical resection or transplantation. Trans-arterial chemoembolization (TACE) is a standard of care used in clinical settings and often combined with targeted therapies. Despite the rise of immunotherapies and precision drugs, chemotherapy remains vital due to its established protocols, lower costs, and widespread availability. Clinical studies are exploring the synergy of chemotherapeutic agents with immunomodulators to prolong survival and delay disease progression. The North American liver cancer therapeutics market was valued at 42.1% market share in 2024. North America is expected to dominate the liver cancer therapeutics market due to its robust healthcare infrastructure, high awareness, and significant investments in oncology research and development (R&D). For instance, in January 2025, researchers at Mount Sinai made a significant breakthrough in treating hepatocellular carcinoma (HCC), a type of liver cancer. Additionally, the rise in liver cancer incidence, driven by NAFLD, obesity, and chronic hepatitis C, has increased early diagnosis rates and demand for advanced therapeutics. The FDA's favorable regulatory pathways, including priority reviews and orphan drug designations, have accelerated drug approval, ensuring rapid market access. The liver cancer therapeutics market in the U.S. dominated the North America market with the largest revenue share in 2024, driven by the increasing investment in pharmaceuticals. The regulatory framework in the U.S. ensures only safe and effective drugs reach the market, which increases trust of patients and healthcare providers in the medicines. Furthermore, the involvement of major players and the launch of novel treatments contribute to its dominance. Regulatory approvals for innovative drugs support market expansion, making the U.S. a leader in liver cancer treatments. This environment fosters continuous innovation and growth. Get Customization in the Report as Per Your Business Requirements: Europe is the second-dominating region in the liver cancer therapeutics market, valued at 34.5% market share in 2024. The liver cancer therapeutics market in Europe is driven by the growing prevalence of hepatitis B and C infections, rising alcohol consumption, and increasing cases of non-alcoholic fatty liver disease (NAFLD). Supportive regulatory approvals for novel immunotherapies, combined with a well-established healthcare infrastructure and government-backed cancer screening programs, are driving the adoption of advanced treatment regimens. In the U.K., a high burden of liver disease linked to obesity, diabetes, and alcohol misuse is accelerating demand for effective HCC treatments. National Health Service (NHS) initiatives to expand early cancer diagnosis, along with faster access schemes for innovative oncology drugs, further drive uptake of immunotherapies and targeted therapies. The Asia-Pacific region in the Liver Cancer Therapeutics Market was valued at 23.5% market share in 2024. This region is witnessing significant growth due to the very high incidence of hepatitis B and C, particularly in China and Southeast Asia, which are leading causes of HCC. Rising investments in healthcare infrastructure, increased clinical trial activity, and expanding patient access to immuno-oncology drugs are driving market growth. In Japan, liver cancer remains a leading cause of cancer mortality, primarily associated with hepatitis virus infections and an ageing population. Strong government support for oncology research, rapid adoption of cutting-edge immunotherapies, and the presence of domestic pharmaceutical players are key factors driving therapeutic innovation and market expansion. For instance, in June 2025, Ono Pharmaceutical Co., Ltd. and Bristol-Myers Squibb K.K. received supplemental approval for their anti-PD-1 antibody, Opdivo, and BMSKK's anti-CTLA-4 antibody, Yervoy, in combination therapy in Japan to expand their use for treating unresectable hepatocellular carcinoma (HCC), a type of cancer. Purchase This Exclusive Report at Just USD 4350 Only: Key Liver Cancer Therapeutics Companies: Top companies in the liver cancer therapeutics market include AstraZeneca, Bayer AG, Eli Lilly, Bristol-Myers Squibb Company, Eisai Co., Ltd., Genentech and among others. Recent Developments in the Market In September 2025, Akeso, Inc. has dosed the first patient in its Phase II registrational trial, evaluating cadonilimab, Akeso's first-in-class PD-1/CTLA-4 bispecific antibody, in combination with lenvatinib for treating advanced hepatocellular carcinoma in patients previously treated with atezolizumab and bevacizumab. In July 2025, Apollo Proton Cancer Centre (APCC) has launched an 'Advanced Liver Cancers Clinic', an integrated clinic for primary liver cancers and liver metastases. Related Reports: Pediatric Oncology Drugs Market Size, Share, Industry, Forecast and Outlook (2024-2031) Cancer Immunotherapy Market Size, Trends & Forecast 2033 Hepatocellular Carcinoma Treatment Market Size, Share, Growth Trends and Forecast Report 2025-2033 About DataM Intelligence 4Market Research: DataM Intelligence 4Market Research is a comprehensive market intelligence platform offering syndicated and customized reports along with expert consulting across multiple industries, including chemicals, healthcare, agriculture, food & beverages, and more. With extensive experience and a strategy-focused approach, DataM provides businesses and individuals with reliable market insights, statistical forecasts, and personalized research solutions to help them make informed decisions and successfully bring innovations to market. To find out more, visit or follow us on Twitter, LinkedIn and Facebook. Contact: Mr. Sai Kiran DataM Intelligence 4market Research LLP Ground floor DSL Abacus IT Park, Industrial Development Area Uppal, Hyderabad, Telangana 500039 USA: +1 877-441-4866 Email: [email protected] Content Source: Visit Our Website: Logo: SOURCE DataM Intelligence 4 Market Research LLP WANT YOUR COMPANY'S NEWS FEATURED ON PRNEWSWIRE.COM? 440k+ Newsrooms & Influencers 9k+ Digital Media Outlets 270k+ Journalists Opted In GET STARTED

Orphan DrugPhase 2Drug ApprovalImmunotherapy

100 Deals associated with Ipilimumab

External Link

KEGG	Wiki	ATC	Drug Bank
D04603	Ipilimumab	L01XC11	DB06186

R&D Status

Approved

10 top approved records.

to view more data

Indication	Country/Location	Organization	Date
Microsatellite instability-high Rectal Cancer	Japan	Bristol-Myers Squibb KK	25 Aug 2025
PD-L1 positive Non-Small Cell Lung Cancer	China	Bristol-Myers Squibb Pharma EEIG	22 Jul 2025
Metastatic hepatocellular carcinoma	Australia	Bristol-Myers Squibb Australia Pty Ltd.	27 Jun 2025
Advanced Hepatocellular Carcinoma	European Union	Bristol Myers Squibb Co.	08 Mar 2025
Advanced Hepatocellular Carcinoma	Iceland	Bristol Myers Squibb Co.	08 Mar 2025
Advanced Hepatocellular Carcinoma	Liechtenstein	Bristol Myers Squibb Co.	08 Mar 2025
Advanced Hepatocellular Carcinoma	Norway	Bristol Myers Squibb Co.	08 Mar 2025
Unresectable Hepatocellular Carcinoma	European Union	Bristol Myers Squibb Co.	08 Mar 2025
Unresectable Hepatocellular Carcinoma	Iceland	Bristol Myers Squibb Co.	08 Mar 2025
Unresectable Hepatocellular Carcinoma	Liechtenstein	Bristol Myers Squibb Co.	08 Mar 2025
Unresectable Hepatocellular Carcinoma	Norway	Bristol Myers Squibb Co.	08 Mar 2025
Mismatch repair-deficient Colonic Cancer	European Union	Bristol-Myers Squibb Pharma EEIG	13 Jan 2025
Mismatch repair-deficient Colonic Cancer	Iceland	Bristol-Myers Squibb Pharma EEIG	13 Jan 2025
Mismatch repair-deficient Colonic Cancer	Liechtenstein	Bristol-Myers Squibb Pharma EEIG	13 Jan 2025
Mismatch repair-deficient Colonic Cancer	Norway	Bristol-Myers Squibb Pharma EEIG	13 Jan 2025
Unresectable Esophageal Squamous Cell Carcinoma	United States	Bristol Myers Squibb Co.	27 May 2022
Esophageal Carcinoma	Japan	Bristol-Myers Squibb KK	26 May 2022
Hepatocellular Carcinoma	United States	Bristol Myers Squibb Co.	10 Mar 2020
Melanoma, Cutaneous Malignant	United States	Bristol Myers Squibb Co.	10 Jul 2018
Colorectal Cancer	United States	Bristol Myers Squibb Co.	16 Apr 2018

Developing

10 top R&D records.

to view more data

Indication	Highest Phase	Country/Location	Organization	Date
Bladder Cancer	Phase 3	United States	Ono Pharmaceutical Co., Ltd.	30 Jan 2022
Bladder Cancer	Phase 3	United States	Sino-American Shanghai Squibb Pharmaceuticals Ltd.	30 Jan 2022
HER2 negative Gastric Cancer	Phase 3	United States	Ono Pharmaceutical Co., Ltd.	05 Nov 2021
HER2 negative Gastric Cancer	Phase 3	Japan	Ono Pharmaceutical Co., Ltd.	05 Nov 2021
HER2 negative Gastric Cancer	Phase 3	Taiwan Province	Ono Pharmaceutical Co., Ltd.	05 Nov 2021
Glioblastoma	Phase 3	United States	National Cancer Institute	01 Sep 2020
Gliosarcoma	Phase 3	United States	National Cancer Institute	01 Sep 2020
Locally Advanced Lung Non-Small Cell Carcinoma	Phase 3	United States	Bristol Myers Squibb Co.	08 Oct 2019
Locally Advanced Lung Non-Small Cell Carcinoma	Phase 3	China	Bristol Myers Squibb Co.	08 Oct 2019
Locally Advanced Lung Non-Small Cell Carcinoma	Phase 3	Japan	Bristol Myers Squibb Co.	08 Oct 2019

Clinical Result

Indication

Phase

Evaluation

View All Results

Study	Phase	Population	Analyzed Enrollment	Group	Results	Evaluation	Publication Date


NCT02408861 (AIDS Malignancy Consortium 095 Study \| AMC 095, CTgov)	Phase 1	AIDS-Related Lymphoma \| Relapsing classical Hodgkin lymphoma \| Lung Cancer ... View more	79	Nivolumab (Dose De-escalation Nivolumab 3 mg/kg (Stratum 1))	fwrmthxgoe = xnlsykqxtp efkbajhpgp (pezjsxnqyb, figapxsaxi - lsqpnvrmlw) View more	-	23 Sep 2025
				Nivolumab (Dose De-escalation Nivolumab 3 mg/kg (Stratum 2))	fwrmthxgoe = rcmqalvgox efkbajhpgp (pezjsxnqyb, hbhwcucqjj - fqbshxliun) View more
NCT04396860 (NRG Oncology BN007, Pubmed \| J Clin Oncol)	Phase 2/3	Glioblastoma MGMT-unmethylated	159	Radiotherapy + Immunotherapy (ipilimumab and nivolumab)	awdxdxpnhy(gouojeyakm) = miahwtokaa cfjgrfvfdc (lrjsnnseqs )	Negative	20 Sep 2025
				Radiotherapy + Temozolomide	awdxdxpnhy(gouojeyakm) = sgyxebauet cfjgrfvfdc (lrjsnnseqs )
NCT03195478 (CheckMate 672, CTgov)	Phase 1/2	Solid tumor \| Relapsed Solid Neoplasm	37	NIVO (Part 1: Arm A)	ozuvvpcbka = libhmiqvgb dgjvgxtxtf (btpyscbbpu, ynhsjaqkil - vylivaurwy) View more	-	15 Sep 2025
				NIVO (Part 1: Arm B)	ozuvvpcbka = iksimklyck dgjvgxtxtf (btpyscbbpu, ebecjnfuae - lotefexfuk) View more
NCT05401786 (RAD-IO, WCLC2025)	Phase 2	Non-Small Cell Lung Cancer	54	IpilimumabCemiplimab + IpilimumabCemiplimab (SBRT)	ayyemqjjhd(vaqqvjsriz) = qpdljpeafq hpqjhtkdqc (rmeovacrqk, 1.5 - 4.2) View more	Positive	09 Sep 2025
NCT03918252 (WCLC2025)	Phase 2	Mesothelioma Neoadjuvant	30	Nivolumab	rwoawhnrdi(wqinziqcyz) = cmqmeyryun wbbhgugqxo (pwudnzrgos, 47.8 - 83.4) View more	Positive	08 Sep 2025
				ipilimumab+Nivolumab	rwoawhnrdi(wqinziqcyz) = qhdxrdxjcg wbbhgugqxo (pwudnzrgos, 56.0 - 90.3) View more
NCT04026412 (CheckMate 73L \| CheckMate73L \| CheckMate -73L, CTgov)	Phase 3	Locally Advanced Lung Non-Small Cell Carcinoma	925	Nivolumab+Ipilimumab (Arm A:Nivo + CCRT/Nivo + Ipi)	ljbbtmcdzf(djmnrainch) = ovfstalhzi evjlgwdbpu (puchwwcolo, fqcqwgbfaa - njejlootmg) View more	-	24 Jul 2025
				Durvalumab (Arm C: CCRT/Durva)	ljbbtmcdzf(djmnrainch) = rxwgacvrbn evjlgwdbpu (puchwwcolo, vyhdnchogl - wblmmoytoy) View more
NCT02553642 (CTgov)	Phase 2	Melanoma \| Bladder Cancer \| Locally Advanced Melanoma	81	Ipilimumab+Nivolumab (Melanoma Cancer Patients)	bqzhbstffc(ewnloemrnh) = jlnxzstxgc pbttvlxzxi (zpxdrwbzkz, mrenvankhm - vgtmnxjqbg) View more	-	22 Jul 2025
				Nivolumab (Bladder Cancer Patients)	zmjlnqdiuy = pkseyfiaiq khtefxahdy (xwivijlurs, effopwkabu - resdzrcffx) View more
NCT04513522 (CheckMate 7C9, CTgov)	Phase 4	Advanced Renal Cell Carcinoma	101	Ipilimumab+Nivolumab	hgmejqidtu = bukxdfxdxb vesqljxwwt (mkhleeohdf, htecbfmrrk - zuacwdfuhp) View more	-	11 Jul 2025
NCT03117309 (HCRN GU16-260 \| HCRN GU16-260-Cohort A, CTgov)	Phase 2	Advanced Renal Cell Carcinoma	164	Nivolumab (Cohort A Part A: Nivolumab Monotherapy in Clear Cell RCC)	kpwzrwhber = nzuwncykph azlsvbzkgj (rvkahqfuoz, gvnyqhusbr - llfjkvewob) View more	-	10 Jul 2025
				Ipilimumab+Nivolumab (Cohort A Part B: Nivolumab and Ipilimumab in Clear Cell RCC)	ufvqrmoqxu = hyurumgymo mdraynucny (vpapeajnnu, drmmrwduus - nojmatperp) View more
NCT03298451 \| NCT04039607 \| NCT03434379 (IMbrave150, ESMO_GI2025) Manual	Not Applicable	Unresectable Hepatocellular Carcinoma First line	-	nivolumab + ipilimumab	eibqzrcmwn(cmozzqdnpc): OR = 2.35 (95% CI, 1.57 - 3.13) View more	Positive	03 Jul 2025
				durvalumab + tremelimumab

Translational Medicine

Boost your research with our translational medicine data.

view full example data

Deal

Boost your decision using our deal data.

view full example data

Core Patent

Boost your research with our Core Patent data.

view full example data

Clinical Trial

Identify the latest clinical trials across global registries.

view full example data

Approval

Accelerate your research with the latest regulatory approval information.

view full example data

Biosimilar

Competitive landscape of biosimilars in different countries/locations. Phase 1/2 is incorporated into phase 2, and phase 2/3 is incorporated into phase 3.

view full example data

Regulation

Understand key drug designations in just a few clicks with Synapse.

view full example data

AI Agents Built for Biopharma Breakthroughs

Accelerate discovery. Empower decisions. Transform outcomes.

Get started for free today!

Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.

Start your data trial now!

Synapse data is also accessible to external entities via APIs or data packages. Empower better decisions with the latest in pharmaceutical intelligence.

Bio

Bio Sequences Search & Analysis

Chemical

Chemical Structures Search & Analysis